PT Mobile Logo

Search form


Brian Miller, MD, PhD, MPH

Brian Miller, MD, PhD, MPH

Dr Miller is Associate Professor in the Department of Psychiatry and Health Behavior at Augusta University in Augusta, GA. Current research focuses on inflammation/cytokines as a potential clinical state and relapse predictive marker in schizophrenia, and is funded by an NIMH K23 Mentored Patient-Oriented Research Career Development Award and the NIH Clinical Loan Repayment Program Award. He has been recognized with several young investigator awards, the 2010 Laughlin Fellowship from the American College of Psychiatrists, and a 2011 Exemplary Psychiatrist Award from the National Alliance on Mental Illness. He is the Schizophrenia Section Editor for Psychiatric Times.

Posts by Author

Which of these agents best prevents relapse? A recent study employed a novel approach to find out.

How widely used is this “gold-standard” antipsychotic?

New findings support the involvement of microbiota alterations in psychosis—and point to novel treatments.

Have antipsychotic and placebo responses in acute schizophrenia changed over time?

Despite increasing awareness of the cardiovascular risks, adequate treatment of the metabolic syndrome remains a persistent challenge.

Monitoring patients for 5 key changes can help avert drug toxicity.

The results of a phase 3 trial demonstrated significant benefit over placebo.

Recent findings suggest metabolic abnormalities may be independent of the effects of antipsychotics.

What’s the optimal approach for patients with treatment-resistant schizophrenia?


By clicking Accept, you agree to become a member of the UBM Medica Community.